This activity is provided by Nexus Healthcare Education and is funded by an independent educational grant from Recordati.

Learning objectives

By participating in this symposium, learners will be better able to:

· Demonstrate knowledge of clinical evidence and guidelines for frontline treatment in favourable-risk mRCC

· Differentiate the efficacy, safety, and quality-of-life impacts of single-agent TKIs and combination therapies

· Develop personalised treatment strategies for mRCC using shared decision-making, integrating prognostic risk, clinical characteristics, and patient preferences

Faculty · Ricky Frazer, Consultant Clinical Oncologist, Velindre Cancer Centre, Cardiff, UK

· Will Ince, Clinical Associate Professor and Consultant Clinical Oncologist, Cambridge University NHS Foundation Trust, Cambridge, UK

· Tom Waddell, Consultant Clinical Oncologist, The Christie NHS Foundation Trust, Manchester, UK

· Laurence Albiges, Head of Department of Oncology, Institut Gustave Roussy, Villejuif, France

Full Agenda

Welcome and introduction: Challenges in the modern era of mRCC management: Ricky Frazer

Frontline treatment in favourable risk mRCC: The role of single-agent TKI therapy versus IO/TKI: Will Ince & Tom Waddell, Moderator: Ricky Frazer

Navigating treatment selection: Choice of single-agent TKI: Will Ince & Tom Waddell, Moderator: Ricky Frazer

Personalising care strategies in favourable risk mRCC: Laurence Albiges Summary and key takeaways: Ricky Frazer